CymaBay Therapeutics

147 articles about CymaBay Therapeutics

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Aug 30, 2021

  8/30/2021

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including Citi’s 16th Annual BioPharma Virtual Conference taking place September 8-10, 2021, the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 and the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2021.

• CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update

  8/12/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2021.

• CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

  8/5/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update.

• CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth

  8/2/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced a $100 million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis, including the Phase 3 RESPONSE clinical trial.

• 

  Clinical Catch-Up: June 21-25

  6/28/2021

  It was a busy week for clinical trial news. Here’s a look.

• CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021

  6/21/2021

  CymaBay Therapeutics, Inc. today announced positive data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis.

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - June 14, 2021

  6/14/2021

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including SVB Leerink CybeRx Series: “Liver Disease Day” Conference taking place June 17, 2021, the Raymond James Human Health Innovation Conference taking place June 22, 2021 and the Piper Sandler “EASL Takeaway Day” taking place June 28, 2021.

• CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021

  6/9/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2021 of the European Association for the Study of Liver.

• CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2021

  5/18/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of an inducement award to Dennis Kim, MD in connection with his appointment as the company’s Chief Medical Officer.

• CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical OfficerExperienced Biotech Executive, Physician-Scientist and Orphan Disease Expert to Lead Clinical/Medical Functions as Seladelpar Advances in Phase 3 and as Pipeline Programs Mature

  5/13/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, MD, MBA, is joining the company as Chief Medical Officer.

• CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/13/2021

  Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team

• CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2021

  5/11/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of an inducement award to Lewis Stuart in connection with his appointment as the company’s Chief Commercial Officer.

• CymaBay Names Lewis Stuart Chief Commercial Officer

  5/10/2021

  Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches  Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions

• CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

  5/6/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2021 and to provide a business update.

• CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors

  4/5/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and commercial leader Janet Dorling to its Board of Directors.

• CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

  3/25/2021

  Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): RESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational study ASSURE, an open-label, long-term study

• CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021

  3/12/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update.

• CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference

  3/11/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered during the NASH-TAG Conference being held March 11 th – 13 th .

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Feb 24, 2021

  2/24/2021

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including the Raymond James 42nd Annual Institutional Investors Conference taking place March 1-3, 2021, the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021, and Oppenheimer’s 31st Annual Healthcare Conference taking place March 16-17, 2021.

• CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

  2/10/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink 10th Annual Global Healthcare Conference taking place February 22-26, 2021.